Justin Rudolph du Toit

Dr. Justin Rudolph du Toit

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JTJustin Rudolph du Toit
Justin Rudolph du Toit
AMAndrew Mcdonald
Andrew Mcdonald
DBDavid Brittain
David Brittain
MCMichael Cass
Michael Cass
JTJacqueline Thomson
Jacqueline Thomson
EVEstelle Verburgh
Estelle Verburgh
Identifying a suitable volunteer unrelated donor (UD) in South Africa is challenging due to the highly diverse ethnic groups and mixed-race populations in this region. Haploidentical hematopoietic cell transplantation (haploHCT) is thus an attractive procedure for patients with high-risk hematologic malignancies. This study was conducted to assess the safety and feasibility of haploHCT in South Africa. We retrospectively analyzed the outcome of 134 patients with hematologic malignancies who received unmanipulated haploHCT with post-transplantation cyclophosphamide at 2 high-volume HCT centers between 2014 and 2019. We assessed overall survival (OS), disease-free survival (DFS), nonrelapse mortality (NRM), relapse incidence (RI), and incidence of acute GVHD. The median recipient age was 44 years (range, 15 to 73 years) and the median donor age was 36 years (range, 9 to 68 years). Acute myelogenous leukemia or myelodysplastic syndrome (AML/MDS) and acute lymphoblastic leukemia (ALL) were the most common indications for haploHCT (61.2%). The European Society for Blood and Marrow Transplantation risk score was ≥5 in 44 patients (32.8%). Seventy-seven patients (57.4%) received a myeloablative conditioning regimen. The majority of patients received a sex-matched transplant (57.4%) and had peripheral blood stem cells (PBSCs) as the stem cell source (70.9%). Sixteen patients (11.9%) had an incongruent cytomegalovirus serostatus at transplantation. The median duration of follow-up was 10.8 months (range, 0.36 to 70.8 months). OS was 56% (95% confidence interval [CI], 47% to 64%) at 1 year and 37% (95% CI, 28% to 47%) at 3 years. DFS was 47% (95% CI, 38% to 55%) at 1 year and 32% (95% CI, 24% to 41%) at 3 years. The 100-day and 3-year cumulative incidence of NRM was 18% (95% CI, 11% to 25%) and 41% (95% CI, 32% to 50%), respectively, and the 1- and 3-year cumulative RI was 16% (95% CI, 11% to 24%) and 21% (95% CI, 14% to 29%), respectively. The 1-year OS was 55% (95% CI, 40% to 67%) for the patients with AML/MDS versus 41% (95% CI, 21% to 60%) for those with ALL. Forty-five patients (41.7%) developed acute GVHD by day +100; of these, 80% had grade I-II disease. Fifty patients (37.5%) developed cytomegalovirus infection that required therapy. On multivariable analysis, older donor age was an independent risk factor for lower DFS. RI was higher for diagnoses other than acute leukemia/MDS (relative risk [RR], 2.62; 95% CI, 1.12 to 6.15; P = .027), decreased for PBSC versus bone marrow (RR, 0.43; 95% CI, 0.19 to 0.95; P = .038) and decreased for offspring donors (RR, 0.25; 95% CI, 0.09 to 0.67; P = .006). These data support the feasibility of haploHCT and suggest that unmanipulated haploHCT using a younger parent or offspring donor is a viable option for adults in sub-Saharan Africa with acute leukemia and MDS who lack a suitable related or unrelated donor.

30 September 2025 in Journal of Intensive Care Medicine
Verified
Journal Article
Open access
SBS. van der Bie
S. van der Bie
RFRamon Fluit
Ramon Fluit
TNT. Neijzen
T. Neijzen
SES.M. Euser
S.M. Euser
EGE.C.M van Gorp
E.C.M van Gorp
MGMarco Goeijenbier
Marco Goeijenbier
Introduction: Viral severe acute respiratory infections (SARI) are a major cause of intensive care unit (ICU) admission, with a significant burden and mortality. Comparative clinical data of patients admitted to the ICU with virus infections other than SARS-CoV-2 or influenza virus (IV) infection are limited. Therefore, this study investigates patient characteristics, clinical outcomes, and ventilation parameters of ICU patients admitted with SARI caused by Respiratory syncytial virus (RSV), Human metapneumovirus (HMPV), IV, or Parainfluenza virus (PIV). Methods: A retrospective cohort study was conducted of patients with SARI admitted to the ICU of the Spaarne Gasthuis, a Dutch secondary teaching hospital, between 2017 and 2023. Results: 277 patients were included, with RSV (n = 51), HMPV (n = 40), IV (n = 142), and PIV (n = 44) infections respectively. Pre-existing hematological malignancies were more common in RSV patients. No significant differences were found in length of hospital stay or ventilation parameters across the respective virus groups. Median duration of ICU stay was four days (IQR 2-7). Bacterial co-infections, pulmonary infiltrates and a higher ROX-index were more common in patients with noninvasive ventilation (NIV) failure. Hospital mortality rates were not different between the groups; RSV (25.5%), HMPV (15%), IV (24.6%), and PIV (20.5%). Conclusion: This study analyzed ICU patients with SARI caused by HMPV, RSV, IV, or PIV, revealing four key findings: high ICU, hospital and 1 year mortality rates with no differences and similar mechanical ventilation parameters between the groups, risk factors for NIV failure linked to prolonged ventilation, and co-morbidities associated with severe disease.

2 March 2022 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
JTJustin Rudolph du Toit
Justin Rudolph du Toit
MGMarco Goeijenbier
Marco Goeijenbier
CTCecile du Toit
Cecile du Toit
PWPieter de Witt
Pieter de Witt
HKHannes Koornhof
Hannes Koornhof
EVEstelle Verburgh
Estelle Verburgh

2 October 2026 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
JDJ Damelin
J Damelin
JJJ Jacobson
J Jacobson
CBC Bam
C Bam
LPL Pillay
L Pillay
JTJustin Rudolph du Toit
Justin Rudolph du Toit
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an adult-onset autoinflammatory disorder first described in 2020, resulting from somatic mutations in the UBA1 gene on the X chromosome. These mutations impair ubiquitin-activating enzyme function, driving a clonal, myeloid-restricted autoinflammatory state. Clinically, VEXAS is characterised by recurrent fevers, neutrophilic and vasculitic skin lesions, relapsing polychondritis, pulmonary infiltrates, venous thromboembolism and progressive cytopenias. A hallmark diagnostic feature is the presence of cytoplasmic vacuoles in myeloid and erythroid precursors. Haematological abnormalities are central to the disease presentation, and myelodysplastic syndromes are common. Given its broad multisystem presentation, VEXAS is frequently misdiagnosed as vasculitis, connective tissue disease, infection, or primary haematological pathology, often resulting in years of ineffective immunosuppression and delayed diagnosis. Mortality remains high, with approximately half of patients dying within 5 years of diagnosis. In South Africa (SA), access to advanced molecular diagnostics (including UBA1 sequencing) remains limited, contributing to under-recognition of the condition. This case is notable in that, to the best of our knowledge, it represents the first reported SA case of VEXAS syndrome with molecular confirmation of a UBA1 mutation.

3 August 2026 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
JTJustin Rudolph du Toit
Justin Rudolph du Toit
ASA Setzer
A Setzer
MSMatthew Seftel
Matthew Seftel
MGMarco Goeijenbier
Marco Goeijenbier
EVE Verburgh
E Verburgh
VLVernon Louw
Vernon Louw
Background. Patients with haematological malignancies and haematopoietic stem cell transplant recipients are major consumers of blood products. In South Africa (SA), both medical oncologists and clinical haematologists (haematology providers) manage these patients. We hypothesised that there may be varied blood transfusion practices between these two specialty groups. Objectives. To compare red blood cell (RBC) and platelet transfusion practices among haematology providers in SA, focusing on transfusion thresholds, blood product modifications and differences between clinical haematologists and medical oncologists. Methods. We conducted an online REDCap survey among SA haematology providers, including clinical haematologists (and trainees), medical oncologists (and trainees), paediatric oncologists/haematologists (and trainees) and medical officers managing haemato-oncology patients. Results. The survey response rate was 51% (79/155), of which 58 (73%) responses were complete and eligible for analysis. RBC and prophylactic platelet transfusion thresholds were generally similar across haematology providers. However, significant variation was observed in platelet thresholds for central venous catheter insertion, lumbar puncture and major surgery. Marked inconsistency was also noted in clinicians’ understanding of when blood product irradiation is indicated. Conclusion. This study confirms a variation in blood transfusion practices and blood product modification requests between haematology providers. This emphasises the need for targeted education and national standardisation efforts to optimise transfusion practice and ensure patient safety.

2 October 2026 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
ASA M Setzer
A M Setzer
SDS Dindayal
S Dindayal
JDJ Damelin
J Damelin
DMD Moodley
D Moodley
DBD Brittain
D Brittain
JTJustin Rudolph du Toit
Justin Rudolph du Toit
Background. Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease that remains a major cause of neurological disability in young adults. While disease-modifying therapies (DMTs) can delay progression, many patients with highly active relapsing- remitting MS (RRMS) continue to experience breakthrough disease. Autologous haematopoietic stem cell transplantation (ASCT) offers durable immune reconstitution and remission but remains underutilised in upper-middle-income settings such as South Africa (SA). Objective. To evaluate the safety, feasibility and clinical outcomes of ASCT for MS in a real-world SA cohort. Methods. We conducted a retrospective record review of all MS patients who underwent ASCT between 1 January 2009 and 31 December 2024 at two JACIE-accredited tertiary centres (Wits Donald Gordon Medical Centre and Netcare Pretoria East Hospital). Data were extracted from institutional transplant records and analysed using descriptive statistics and Kaplan-Meier survival estimates. The primary outcome was the safety of ASCT for MS, and the secondary outcomes were the clinical outcomes of patients who underwent ASCT for MS. Results. Thirty-two patients were included (median age 42 years; 53% female; 94% RRMS). Median disease duration prior to ASCT was 7.4 years, and 97% had received prior DMTs. Conditioning included cyclophosphamide (97%), anti-thymocyte globulin (69%) and fludarabine (34%). The median neutrophil and platelet engraftment occurred at 10 and 14 days, respectively. Relapse-free survival was 100% at 1 year and 91% (95% confidence interval 68 - 98) at 5 years. Approximately 90% of evaluable patients demonstrated neurological improvement or stabilisation at 1 year. Treatment-related adverse events occurred in 63% of cases, and 95% of these side-effects were grade 3 or less: most commonly neutropenic fever (50%) and mucositis (16%). Only 5% of adverse reactions were grade 4, with no transplant-related mortality. Conclusion. ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA. Its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs. The expansion of accredited national ASCT programmes and registry-based outcome monitoring is warranted.